
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is a well-positioned global life science tools company with a strong presence in the US (55% of revenue) and Europe, Middle East, and Africa (20%) markets. The company's sales have been impacted by some adverse timing in the cell therapy segment, but this is expected to improve in the future. The company has a solid portfolio of products and a transformative acquisition of Wilson Wolf, a leader in cell therapy manufacturing, which is not yet fully appreciated by investors.
Bears say
Bio-Techne is facing numerous risks in the near future, including end-market recovery delays, potential share loss to competitors, challenges in the progress of cell therapy development, and risks associated with company acquisitions. Additionally, there is the potential for market share to be lost to companies that have been acquired by larger competitors. While Bio-Techne shows commitment to sustainability practices, there is not currently a direct link between these practices and executive compensation, which could create potential risks for the company's long-term performance and growth. Overall, these factors contribute to our negative outlook on Bio-Techne's stock.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares